FIGURE 10 Upon investigating publication bias, an asymmetric distribution in the funnel plot suggested potential bias
Trial Metric Retatrutide 12mg (TRIUMPH-4) Semaglutide 2.4mg (STEP 1) Mean Weight Loss 28.7% at 68 weeks 14.9% at 68 weeks Mechanism Triple agonist (GLP-1/GIP/GCGR) Single agonist (GLP-1) FDA Status Phase 3 (investigational) Approved (Wegovy) Dosing Weekly subcutaneous Weekly subcutaneous Common Adverse Events GI (nausea, vomiting, diarrhea), dysesthesia GI (nausea, vomiting, diarrhea) Important caveat: These results come from different trial populations and study designs
Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial
Retrieved from Novo Nordisk-b
Rodriguez, PhD MPH Truveta, Inc , Bellevue, WA, Samuel Gratzl PhD Truveta, Inc , Bellevue, WA, Charlotte Baker DrPH MPH CPH Truveta, Inc , Bellevue, WA, Christopher M
Patients who switched from sermorelin to ipamorelin report fewer side effects like flushing and water retention